Presage Biosciences

MedTech

Takeda, Presage microdose cancers to see how immune cells fight

Takeda is examining two therapies that could help break down the barriers protecting solid tumors from the body's immune system.
Conor Hale Apr 13, 2022 4:34pm

Merck taps tumor-microdosing Presage for phase 0 trials

Mar 2, 2021 9:50am

Presage inks 3rd deal around phase 0 studies—with more to come

Aug 27, 2019 8:00am

Celgene taps Presage's microdosing tech for phase 0 cancer studies

May 2, 2019 8:00am

Celgene, Takeda invest in intratumoral microdosing firm Presage

Jul 17, 2018 8:00am